FDA Declines to Approve Achieve Life Sciences' Cytisinicline for Smoking Cessation, Citing Manufacturing Issues Only
Key Insights
The FDA issued a complete response letter for cytisinicline, declining approval solely due to third-party manufacturing facility issues and incomplete product labeling, with no clinical efficacy or safety deficiencies identified.
Achieve's late-stage trials involving over 1,500 participants demonstrated that cytisinicline helped more adults quit smoking than placebo, with benefits lasting through 24 weeks and no new safety concerns.
The company has moved manufacturing to U.S.-based Adare Pharma Solutions (search) and plans to resubmit its application in Q4 2026, with potential FDA approval in the first half of 2027.
The U.S. Food and Drug Administration has declined to approve Achieve Life Sciences' investigational smoking-cessation drug cytisinicline, the company announced Monday. The agency issued a complete response letter (CRL) citing unresolved issues found at a third-party manufacturing facility and final product labeling that was not completed by the FDA's action date.
Critically, the FDA did not identify any deficiencies related to the drug's clinical efficacy or safety in its complete response letter, Achieve emphasized in its statement. This distinction has buoyed investor confidence, with shares of the company rising more than 10% in early trading following the announcement.
"The CRL was expected, but the absence of clinical efficacy or safety deficiencies is the key positive, in our view, as it supports cytisinicline's approvability," said H.C. Wainwright analyst Brandon Folkes.
A Plant-Derived Approach to Nicotine Dependence (search)
Cytisinicline is a plant-derived compound designed to help adults quit smoking by targeting nicotine receptors (search) in the brain. The drug aims to reduce nicotine cravings and withdrawal symptoms, including irritability, anxiety, and sleep problems. Unlike nicotine replacement products such as patches, gums, and lozenges, cytisinicline does not deliver nicotine to the user.
The rejection delays Achieve's bid to introduce another non-nicotine prescription option for adults trying to quit smoking. Currently, FDA-approved pharmacotherapy choices remain largely limited to Pfizer's Chantix and GSK's Zyban, apart from nicotine replacement products.
Clinical Evidence Supporting Cytisinicline
Achieve reported that late-stage trials and safety studies involving over 1,500 participants demonstrated cytisinicline helped more adults quit smoking than placebo. The benefits lasted through 24 weeks, and no new safety concerns were identified in longer-term data. The FDA's complete response letter did not challenge any of these clinical findings.
Manufacturing Transition and Path Forward
The company had previously signaled that a complete response letter was likely after its former third-party manufacturer received an FDA inspection classification requiring corrective action. Achieve noted that the issues were general manufacturing matters and not specific to cytisinicline.
Achieve has since moved its manufacturing to U.S.-based Adare Pharma Solutions (search). The company plans to resubmit its application for cytisinicline in the fourth quarter of 2026, with potential FDA approval anticipated in the first half of 2027. A U.S. commercial launch would follow if the drug is approved.
Market Opportunity
"Smoking cessation is a very large market that has been underdeveloped for years," Folkes said, adding that he believes "cytisinicline has the potential to re-activate" it. The analyst's comments underscore the commercial significance of bringing a new non-nicotine prescription option to patients seeking to overcome tobacco dependence.